5 COVID-19 drugs included in the EU priority accelerated review: 4 antibodies and 1 JAK inhibitor

Compilenewborn

In the fight against epidemic variants, the European Union has identified five COVID-19 treatment drugs, which will be reviewed on a priority basis, and it is hoped that three of them will be approved by October

Specifically, the EU has selected 4 monoclonal antibody programs, including: Eli Lilly antibody cocktail bamlanivimab/etesevimab, Celltrion regdanvimab, Roche/regeneron antibody cocktail casirivimab/imdevimab, Vir/GSK sotrovimab

Also selected was Eli Lilly’s oral JAK inhibitor Olumiant (baricitinib), a drug that has been approved for the treatment of rheumatoid arthritis and atopic dermatitis

This work aims to provide greater regulatory flexibility through rolling reviews, conditional marketing authorizations, and flexible labeling and packaging requirements

To this end, the EU will hold an industry "blind date conference" on July 12th and 13th

An obvious leader is the antibody cocktail therapy from Regeneron

Eli Lilly’s antibody cocktail bamlanivimab/etesevimab is the first drug approved in the United States to treat patients at high risk of developing severe COVID-19

GSK/Vir’s sotrovimab antibody was licensed for use in the United States last month, but the two companies have not yet reached a supply agreement with the U.

In October last year, Europe purchased 500,000 doses of Gilead’s antiviral drug Remdesivir for US$1.

In a statement, the EU said: “The EU hopes to add more promising treatments to this investment portfolio in the fight against COVID-19, reaching 10 by the end of the year, but this will depend on the results of research and development

Reference source: Regeneron, GlaxoSmithKline and Eli Lilly COVID-19 drugs prioritized for expedited review in Europe